PMC Group buys India drugmaker, plans to be a 'major market player' in generics
The Mount Laurel chemical and plastics conglomerate has purchased Yegna Manojavam Drugs and Chemicals Ltd., its offices and factory in Hyderabad. The price was not disclosed.
PMC Group Inc., the Mount Laurel chemical and plastics conglomerate, says it plans to become a "major market player" in the global low-cost generic drugs and drug-materials businesses with its purchase of drugmaker Yegna Manojavam Drugs and Chemicals Ltd., its offices and factory in Hyderabad, India. The price was not disclosed.
"This acquisition begins our journey toward building a global pharmaceutical business," said Raj Chakrabarti, vice president and chief strategy officer of the parent company's PMC Group International unit.
Yegna Manojavam makes antibiotic fluoroquinolone drugs (Ciprofloxacin, Norfloxacin, Enrofloxacin, Tramadol). PMC says his company also plans to focus on oncology (cancer-fighting), antidepressant, anti-migraine and neuropsychiatry, gastrointestinal and pulmonary-hypertension treatments.
PMC was founded by former PPG executive Paritosh M. Chakrabarti in 1994. The company has yearly sales of more than $300 million, according to D&B Hoover, the private-company data firm.
PMC previously purchased units of Dow Chemical Co., King of Prussia-based Arkema Americas, and Philadelphia-based Chemtura, among others. The company says it has customers in the plastics, consumer products, electronics, paint, packaging, personal care, food, automotive and pharmaceuticals industries in the Americas, Europe and Asia.